Metraipolis › archive › dc_07f4e5506c69

Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance — Europe PMC PMID:42357520

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42357520
DOI
10.3390/molecules31122124
License (as archived)
solo-consultazione
Archived
2026-10-31T10:28:39.176Z
SHA-256 of the archived text
240a71a997cdade72981519590d247a7b5509ffedd98934ec98b8dca39c3a75f
Stable URL of this page
https://metraipolis.com/documento/dc_07f4e5506c69

How to cite

Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance — Europe PMC PMID:42357520 — Europe PMC (en), https://europepmc.org/article/MED/42357520 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_07f4e5506c69 (Metraipolis archive dc_07f4e5506c69, sha256 240a71a997cdade72981519590d247a7b5509ffedd98934ec98b8dca39c3a75f)
BibTeX
@misc{dc07f4e5506c69,
  title = {Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance — Europe PMC PMID:42357520},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42357520},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_07f4e5506c69; sha256 240a71a997cdade72981519590d247a7b5509ffedd98934ec98b8dca39c3a75f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42357520. Agents can read the archived copy with the MCP tool read_document.